EA202191984A1 - Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза - Google Patents

Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза

Info

Publication number
EA202191984A1
EA202191984A1 EA202191984A EA202191984A EA202191984A1 EA 202191984 A1 EA202191984 A1 EA 202191984A1 EA 202191984 A EA202191984 A EA 202191984A EA 202191984 A EA202191984 A EA 202191984A EA 202191984 A1 EA202191984 A1 EA 202191984A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
pharmaceutical composition
acute
agent
myeloleukosis
Prior art date
Application number
EA202191984A
Other languages
English (en)
Inventor
Ин Хван Бэ
Чжи Сук Ким
Чже Юль Чой
Ён Гиль Ан
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Priority claimed from PCT/KR2020/002536 external-priority patent/WO2020171646A1/ko
Publication of EA202191984A1 publication Critical patent/EA202191984A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены фармацевтическая композиция для лечения острого миелолейкоза (AML) и способ лечения острого миелолейкоза с ее использованием, где композиция содержит ингибитор Fms-подобной тирозинкиназы-3 (FLT3) или его фармацевтически приемлемые соль или сольват и гипометилирующий агент (НМА) или его фармацевтически приемлемые соль или сольват в терапевтически эффективной комбинации.
EA202191984A 2019-02-22 2020-02-21 Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза EA202191984A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190021228 2019-02-22
KR1020200021502A KR20200102949A (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
PCT/KR2020/002536 WO2020171646A1 (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물

Publications (1)

Publication Number Publication Date
EA202191984A1 true EA202191984A1 (ru) 2021-11-19

Family

ID=72470030

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191984A EA202191984A1 (ru) 2019-02-22 2020-02-21 Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза

Country Status (8)

Country Link
EP (1) EP3928780A4 (ru)
KR (1) KR20200102949A (ru)
CN (1) CN113490497A (ru)
AU (1) AU2020226111A1 (ru)
CA (1) CA3130244A1 (ru)
EA (1) EA202191984A1 (ru)
IL (1) IL285628A (ru)
SG (1) SG11202108867VA (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650823A (zh) * 2019-06-27 2022-06-21 韩美药品株式会社 用于治疗急性髓系白血病的含有flt3抑制剂和化疗剂的药物组合物
EP4370127A2 (en) * 2021-07-12 2024-05-22 Quteba Ebrahem A method of treating cancer or a blood disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005621A (es) 2006-11-28 2009-06-12 Novartis Ag Combinacion de inhibidores de iap e inhibidores de flt3.
KR20180124055A (ko) 2016-03-29 2018-11-20 아스테라스 세이야쿠 가부시키가이샤 급성 골수성 백혈병의 치료를 위한 병용 요법
PT3514153T (pt) * 2017-01-26 2021-09-22 Hanmi Pharm Ind Co Ltd Composto de pirimidina e utilização farmacêutica do mesmo

Also Published As

Publication number Publication date
KR20200102949A (ko) 2020-09-01
EP3928780A4 (en) 2022-12-07
SG11202108867VA (en) 2021-09-29
CN113490497A (zh) 2021-10-08
AU2020226111A1 (en) 2021-09-09
EP3928780A1 (en) 2021-12-29
IL285628A (en) 2021-09-30
CA3130244A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
EA202290154A1 (ru) Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
NI201800102A (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1, 5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
NZ758548A (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
MX370099B (es) Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
EA202191984A1 (ru) Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
WO2018102687A3 (en) Combination therapy for treating cancer
MX2021002321A (es) Nuevos metodos.
MX2021002322A (es) Nuevos metodos.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
MX2022004027A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida.
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
PH12020551772A1 (en) Oxo-substituted compound
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
MX2022005199A (es) Inhibidores de ssao y uso de los mismos.
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.